March 28th 2023
Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
The 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
5/13/2023
View More
Community Practice Connections®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
View More
Medical Crossfire®: How Are We Personalizing Integration of ICIs and Targeted Therapies to Optimize Outcomes in Endometrial Cancer?
View More
Medical Crossfire®: How Are We Integrating Immune Checkpoint Inhibitors and Targeted Therapies to Personalize Therapy in Endometrial Cancer?
View More
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
View More
Burst CME™: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment
View More
HPV Vaccine Not Linked to Serious Complications in Adult Women
October 22nd 2017A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
Extending Platinum-Free Interval in Ovarian Cancer Does Not Improve Outcomes
October 18th 2017Extending the platinum-free interval following disease progression in ovarian cancer with a non-platinum agent does not improve outcomes over the standard practice of using a platinum-based chemotherapy, according to a prospective trial.
USPSTF Proposes New Guidelines for Cervical Cancer Screening
October 11th 2017The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.
No Survival Benefit With Adjuvant Chemo for Most Endometrioid, Ovarian Clear Cell Cancers
October 9th 2017A large database study found that most patients with stage I endometrioid epithelial ovarian cancer or ovarian clear cell cancer do not have better survival outcomes when treated with adjuvant chemotherapy.
Dose-Dense Chemotherapy Fails to Improve PFS in Ovarian Cancer
September 8th 2017Weekly dose-dense chemotherapy can be delivered successfully and with lower toxicity than standard 3-weekly regimens, but it does not improve progression-free survival among patients with epithelial ovarian cancer, according to a large new study presented at the ESMO.
Endometrial Cancer Patients Not Offered Genetic Counseling Referrals
June 19th 2017According to a study recently presented at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago, women diagnosed with endometrial cancer are oftentimes not provided with genetic counseling referrals.
Olaparib Associated With Improved Quality of Life in Ovarian Cancer
June 3rd 2017Despite toxicity, olaparib maintenance therapy is associated with improved patient-reported symptoms outcomes and improved quality-adjusted progression-free survival among patients with germline BRCA mutation-positive, platinum-sensitive relapsed serious ovarian cancer.
Some Older Women Still Need Cervical Cancer Screening
May 17th 2017The number of women who undergo regular screening for cervical cancer drops as they get older, and while this is acceptable if women have been followed regularly until the age of 65 years, women who are not up to date with screening should be screened when they are older.
COUNTERPOINT: Is Lymphadenectomy Required in Endometrial Cancer for Adequate Surgical Staging?
May 15th 2017The question that should be posed to those who advocate for lymphadenectomy as a tool to guide the adjuvant therapy of endometrial cancer is: At what cost to the patient is lymphadenectomy performed?